Results for untargeted MS search on m/z: (+/-) mode (maximum rows displayed:1000)
| Details | Name | m/z | RT | RT_Units | Study | Ion_mode | MS_Instrument | Chromatography | Species | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| AN005416 | 111.0065 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 111.0065 | 1.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 112.9817 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 114.9864 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 116.0687 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 116.0698 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 117.0172 | 1.75 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 121.0267 | 5.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 122.0318 | 5.6 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 128.0318 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 129.0372 | 1.42 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 129.0531 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 129.0532 | 4.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 130.0583 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 130.0588 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 130.0847 | 1.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 130.9451 | 18.41 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 130.9454 | 18.19 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 131.0339 | 3.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 133.0118 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 134.0057 | 5.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 134.0452 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 134.0454 | 1.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 135.0300 | 1.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 135.0303 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 136.8638 | 19.67 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 136.9177 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 144.8705 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 144.9666 | 1.06 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 145.0513 | 2.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 145.0605 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 145.0977 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 146.0443 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 146.8667 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 146.9812 | 1.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 147.0449 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 148.0435 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 148.9797 | 1.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 150.0017 | 8.12 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 150.8865 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 151.0408 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 152.8835 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 154.9264 | 0.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 156.9249 | 0.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 157.0121 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 157.0514 | 4.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 157.0516 | 3.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 158.0832 | 5.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 158.9762 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 160.8430 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 161.0820 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 162.8402 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 163.0408 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 164.0701 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 164.9282 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 164.9300 | 19.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 164.9551 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 165.0201 | 5.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 165.9790 | 9.04 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 168.0646 | 0.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 168.9891 | 6.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 169.0730 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 171.0673 | 7.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 171.1141 | 3.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 171.1148 | 3.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 172.0990 | 6.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 172.0991 | 6.02 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 173.0842 | 6.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 173.1049 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 173.1202 | 10.39 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 174.0403 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 174.0406 | 1.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 175.0251 | 0.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 175.0266 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 176.9372 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 178.0552 | 4.51 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 178.9519 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 179.0563 | 1.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 179.0568 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 180.0650 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 180.9727 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 181.0519 | 4.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 183.0136 | 17.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 183.0140 | 16.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 183.0141 | 19.6 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 183.0290 | 2.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 185.0126 | 0.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 185.0132 | 1.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 185.9923 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 185.9934 | 1.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 186.9286 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 187.0157 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 187.0157 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 187.0425 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 187.0996 | 8.01 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 187.9907 | 1.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 187.9918 | 1.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 188.0558 | 1.39 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 188.0560 | 1.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 188.0933 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 188.0936 | 1.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 189.9736 | 0.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 190.0558 | 4.47 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 190.0727 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 190.9308 | 0.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 190.9315 | 2.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 190.9745 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 191.0185 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 191.0187 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 192.0485 | 9.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 192.0666 | 5.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 193.0898 | 11.24 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 193.0926 | 9.59 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 194.0843 | 12.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 195.0473 | 7.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 195.8126 | 0.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 196.0233 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 197.0083 | 1.18 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 197.0438 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 197.0439 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 197.0454 | 4.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 197.8095 | 0.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 198.0754 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 198.0755 | 1.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 199.0779 | 10.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 199.8071 | 0.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 201.0373 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 201.1160 | 9.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 202.1084 | 1.9 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 202.1109 | 6.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 203.0065 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 203.0215 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 203.0581 | 3.67 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 203.0820 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 205.0129 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 205.0754 | 3.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 205.0902 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 205.0995 | 4.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 205.8420 | 0.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 206.0036 | 1.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 206.0843 | 6.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 207.0132 | 6.4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 207.8390 | 0.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 208.8458 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 210.8424 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 212.8407 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 212.8881 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 212.9567 | 1 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 212.9815 | 6.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 213.0139 | 8.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 213.0203 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 213.0402 | 2.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 213.0865 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 213.1525 | 11.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 213.9638 | 5.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 214.8859 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 215.0316 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 215.0855 | 4.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 215.1322 | 10.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 215.1759 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 216.9275 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 216.9836 | 1.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 216.9839 | 1.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 217.0291 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 217.0735 | 5.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 217.9370 | 0.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 218.1031 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 218.8744 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 218.9847 | 0.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 218.9860 | 18.58 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 218.9860 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 218.9861 | 17.41 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 219.0376 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 219.0796 | 2.22 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 220.0667 | 1.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 220.1108 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 220.1486 | 12.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 220.8724 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 221.1221 | 11.1 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 221.1575 | 14.58 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 222.0323 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 225.0616 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 225.0953 | 11.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 226.9671 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 226.9702 | 18.36 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 226.9705 | 19.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 227.0566 | 3.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 227.0615 | 12.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 228.1647 | 9.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 228.9035 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 229.1366 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 229.1478 | 11.39 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 229.9450 | 6.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 231.9703 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 232.0591 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 232.1215 | 1.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 232.9433 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 232.9859 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 233.0965 | 7.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 233.1058 | 5.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 233.1570 | 14.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 234.1533 | 13.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 234.8684 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 235.1412 | 12 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 235.9285 | 0.62 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 236.0935 | 3.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 236.0957 | 3.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 236.0962 | 7.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 236.0991 | 9.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 236.1078 | 12.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 236.8667 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 238.0264 | 1.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.0566 | 5.36 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.0617 | 18.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.0635 | 18.6 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.0703 | 14.03 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.1040 | 3.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.1324 | 12.59 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 239.8973 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 240.0249 | 1.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 240.0501 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 241.0724 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 241.0724 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 241.0758 | 7.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 242.0834 | 12.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 242.1786 | 10.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 242.9457 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 242.9463 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.0631 | 1.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.0863 | 7.75 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.1637 | 12.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.2007 | 13.5 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.2008 | 15.26 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.2011 | 15.67 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 243.9522 | 1.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 244.1215 | 2.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 245.1425 | 8.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 245.9497 | 1.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 246.0474 | 4.9 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 246.9629 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 247.0250 | 1.4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 247.9911 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 247.9950 | 1.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 248.0548 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 248.9596 | 0.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 248.9981 | 5.31 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 249.0262 | 10.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 249.0351 | 8.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 249.1282 | 8.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 249.1531 | 15.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 249.1561 | 13.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 249.9869 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 250.0195 | 1.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 250.0282 | 5.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 250.0577 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 250.0959 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 250.1154 | 8.75 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 250.1465 | 15.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 252.0897 | 1.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 252.9821 | 1.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 253.1487 | 11.68 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 254.9193 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 254.9680 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 255.1167 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 255.1173 | 7.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 255.1178 | 7.39 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 255.1186 | 11.22 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 257.1797 | 16.21 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 257.1800 | 13.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 257.9951 | 1.42 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 258.9992 | 1.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 259.0162 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 259.0162 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 259.0170 | 4.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 259.0798 | 0.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 260.0475 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 260.0477 | 1.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 260.0563 | 5.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 260.0588 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 260.9816 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 261.0435 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 262.9778 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 263.0104 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 263.0419 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 263.8823 | 9.04 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 264.0124 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 264.1635 | 15.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.0342 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.0346 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.0853 | 3.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.1484 | 15.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.3085 | 15.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.4390 | 15.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 265.8803 | 9.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 266.1058 | 3.14 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 267.0734 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 267.8106 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 268.0004 | 1.59 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 268.0787 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 268.1381 | 13.18 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 268.8001 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 269.0278 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 269.0571 | 0.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 269.0854 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 269.0884 | 1.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 269.2165 | 14.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 269.9600 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 270.7974 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 270.8474 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 270.9623 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 271.2316 | 14.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 271.2316 | 16.47 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 271.2317 | 15.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 271.2317 | 16.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 271.2319 | 15.31 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.0915 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.2029 | 13.97 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.7959 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.8444 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.9591 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.9599 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 272.9950 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 273.0891 | 4.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 273.0960 | 13.14 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 273.1270 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 274.1510 | 12.02 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 275.0030 | 6.4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 275.0564 | 0.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 275.1066 | 4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 275.1433 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 275.1721 | 17.41 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 275.8962 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 276.0644 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 276.0890 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 276.8321 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 276.8363 | 0.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 276.8871 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.0208 | 5.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.0217 | 7.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.0350 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.0585 | 10.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.0646 | 3.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.1483 | 14.34 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.1493 | 15.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 277.1850 | 13.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 278.0629 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 278.1064 | 3.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 278.1247 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 278.1250 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 278.8289 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 279.0397 | 1.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 279.0586 | 1.42 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 279.0883 | 4.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 279.1672 | 17.34 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 280.1043 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 280.8272 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 280.8772 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 281.0377 | 1.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 281.0755 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 281.1019 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 281.1020 | 4.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 281.2523 | 17.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 281.9541 | 5.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 282.0863 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 282.7803 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 283.1049 | 11.97 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 283.1412 | 14.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 283.1412 | 15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 283.1667 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 283.1678 | 1.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 284.0055 | 3.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 284.1342 | 11.19 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 284.2265 | 15.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 284.9537 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 285.1297 | 12.36 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 285.1692 | 11.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 285.2115 | 14.68 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 285.2121 | 13.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 285.9206 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 285.9448 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.0619 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.0915 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.1377 | 15.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.7746 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.8226 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.8620 | 0.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.9745 | 13.5 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 286.9751 | 19.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 287.0460 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 287.0917 | 3.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 287.1424 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 287.1437 | 9.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 287.2273 | 13.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 287.9767 | 16.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 288.0917 | 0.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 288.8592 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 288.9366 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 288.9415 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 289.0691 | 1.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 289.1027 | 9.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 289.1048 | 5.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 289.1053 | 7.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 289.1097 | 11.1 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 290.0217 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 290.0977 | 7.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 291.1030 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 291.1627 | 14.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 292.0820 | 1.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 292.0831 | 1.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 292.1399 | 1.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 292.8282 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.1772 | 12.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.1800 | 13.03 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.1805 | 19.38 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.1828 | 14.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.1837 | 15.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.2150 | 15.4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 293.2152 | 15.22 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 294.0316 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 294.0889 | 3.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 294.8250 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 294.9549 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 295.0454 | 1.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 295.2302 | 15.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 295.2320 | 15.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 295.2323 | 15.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 296.1491 | 14.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 296.8247 | 0.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 296.8904 | 0.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 297.1206 | 13.18 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 297.1534 | 16.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 297.2453 | 16.18 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 297.2465 | 15.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 297.3239 | 16.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 297.9869 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 298.0092 | 1.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 298.0715 | 1.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 298.0716 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 298.2511 | 15.46 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 298.9455 | 9.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 299.2027 | 16.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 299.2599 | 16.14 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 300.0250 | 1.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 300.0493 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 300.1962 | 3.41 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 300.2340 | 15.31 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 300.9317 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 301.1254 | 13.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 301.1608 | 15.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 301.1621 | 15.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 301.2216 | 16.73 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 301.9110 | 1.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 303.0519 | 1.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 303.2355 | 17.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 303.7889 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 303.9089 | 1.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 304.0838 | 3.19 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 304.0839 | 5.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 304.9174 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 305.0861 | 11.12 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 305.1006 | 9.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 305.1561 | 9.12 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 305.9542 | 1.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 306.0762 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 306.0805 | 3.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 306.2053 | 0.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.0360 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.0832 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.1129 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.1495 | 0.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.1632 | 15.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.2851 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 307.4262 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 308.0989 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1048 | 1.42 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1211 | 4.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1221 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1575 | 15.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1585 | 13.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1743 | 12.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1751 | 12.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.1759 | 17.46 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 309.9863 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.0267 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.0980 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.1527 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.1668 | 10.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.1791 | 12.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.9334 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.9349 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.9799 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 310.9808 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.1691 | 17.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.2036 | 15.67 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.2266 | 12.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.2641 | 16.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.3428 | 17.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.3431 | 18.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 311.4842 | 17.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 312.0956 | 1.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 312.9276 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 313.0533 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 313.1306 | 8.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 313.2261 | 16.97 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 313.2417 | 14.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 313.2425 | 13.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 314.2496 | 15.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.0997 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.1081 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.1090 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.1993 | 14.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.2008 | 11.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.2008 | 14.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.2014 | 13.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.2579 | 14.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 315.2581 | 14.68 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 316.0439 | 1.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 316.0961 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 316.1500 | 16.01 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 316.1507 | 15.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 316.9468 | 0.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 316.9518 | 16.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 317.1559 | 15.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 317.1583 | 14.49 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 317.1584 | 14.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 317.2156 | 15.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 317.2165 | 16.54 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 317.2168 | 15.5 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 318.0120 | 1.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 318.0694 | 4.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 318.1406 | 2.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 318.1408 | 3.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 318.9405 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 319.1047 | 15.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 319.2317 | 15.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 319.2321 | 15.19 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 320.0575 | 2.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 320.1283 | 5.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 320.8405 | 0.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 320.9371 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 321.0690 | 1.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 321.0707 | 1.68 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 321.0957 | 6.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 321.1789 | 17.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 321.1860 | 10.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 321.2141 | 16.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 322.0278 | 5.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 322.2183 | 16.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 322.8591 | 1.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 322.9065 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 322.9285 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 323.0221 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 323.0313 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 323.1730 | 17.51 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 323.9325 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 325.0322 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 325.0339 | 2.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 325.0581 | 7.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 325.1847 | 19.6 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 325.3627 | 19.59 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 325.9833 | 1.42 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 326.7595 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.0051 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.0054 | 4.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.0316 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.0683 | 0.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.1321 | 3.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.2357 | 17.03 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 327.2589 | 16.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.0448 | 5.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.1761 | 13.59 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.2655 | 16.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.7569 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.8053 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.8606 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 328.9207 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.1202 | 13.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.1226 | 14.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.1243 | 1.9 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.1578 | 14.46 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.2369 | 13.68 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.2524 | 17.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 329.2524 | 17.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 330.1185 | 15.21 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 330.1204 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 330.1500 | 7.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 330.7554 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 330.8019 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 330.9188 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.0042 | 1.4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.0923 | 1.47 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.1233 | 1.9 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.1248 | 15.21 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.1342 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.1375 | 12.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.2532 | 12.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 331.2694 | 17.87 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.0619 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.1307 | 15.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.1762 | 14.1 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.1765 | 13.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.1767 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.8009 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.9245 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.9496 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 332.9615 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0226 | 5.31 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0428 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0922 | 9.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0942 | 7.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0952 | 7.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0957 | 1.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0958 | 11.22 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.0965 | 1.54 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.1132 | 0.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.1382 | 15.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.1542 | 13.73 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.1545 | 14.01 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 333.1551 | 14.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 334.0527 | 1.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 334.0533 | 1.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 334.1023 | 5.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 334.1800 | 3.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 334.7928 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 335.0624 | 2.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 335.2254 | 14.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 335.2265 | 12.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 335.2266 | 12.62 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 336.0850 | 1.54 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 336.7883 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 336.8862 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 336.8888 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 337.0173 | 1.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 337.0196 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 337.0480 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 337.0579 | 12.02 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 337.1891 | 19.47 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 337.2089 | 13.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 338.0598 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 338.0671 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 338.0802 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 338.8353 | 0.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 339.0157 | 1.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 339.0171 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 339.0602 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 339.2000 | 14 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 339.2321 | 16.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 339.9957 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 340.0612 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 340.2911 | 17.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 340.7395 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 340.8329 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 340.9492 | 0.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 341.0368 | 1.42 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 341.9032 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 342.0899 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 342.1196 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 342.1500 | 8.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 342.2798 | 16.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 343.0734 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 343.0735 | 4.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 343.1727 | 11.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 343.1746 | 14.51 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 343.9255 | 5.49 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.0203 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.0998 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.1009 | 7.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.1374 | 3.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.1386 | 5.55 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.1391 | 5.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 344.7337 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 345.0913 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 345.1362 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 345.1362 | 1.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 345.1377 | 15.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 345.1730 | 13.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 345.2685 | 16.21 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 346.1140 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 346.1465 | 15.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 346.2159 | 16.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 347.0504 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 347.0763 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 348.0068 | 12.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 348.0642 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 348.1079 | 15.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 348.8173 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 349.0619 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 349.0903 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 349.0909 | 4.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 350.7868 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 351.0367 | 8.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 351.1042 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 351.1332 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 351.1543 | 1.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 351.1545 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.0446 | 7.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.0447 | 9.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.0693 | 6.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.0797 | 5.94 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.2148 | 15.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.2282 | 11.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 352.7835 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.0528 | 9.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.0529 | 11.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2040 | 18.58 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2170 | 0.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2183 | 15.82 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2201 | 16.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2205 | 15.67 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2342 | 7.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2370 | 11.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2441 | 17.22 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.2865 | 7.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.3378 | 7.75 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.3873 | 7.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.4855 | 7.75 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 353.9097 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 354.0571 | 7.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 354.0807 | 3.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 354.7832 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 354.9554 | 9.04 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 354.9627 | 19.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 355.1623 | 17.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 355.2011 | 15.99 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 355.9435 | 1.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 356.0724 | 7.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 356.1237 | 1.9 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 356.3010 | 17.22 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 356.9259 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 357.0923 | 3.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 357.0976 | 11.1 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 357.1894 | 13.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 358.2429 | 15.41 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 358.8394 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 358.9825 | 1.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 359.8694 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 360.0732 | 1.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 360.1281 | 1.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 360.1601 | 7.49 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 361.1392 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 361.1661 | 12.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 361.1703 | 19.38 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 361.1804 | 8.7 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 361.7486 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 361.8670 | 1.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.0210 | 3.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.0702 | 15.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.0718 | 15.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.1435 | 15.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.1440 | 14.92 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.1500 | 6.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.2125 | 14.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 362.9413 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 363.1106 | 3.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 363.2183 | 15.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 364.2179 | 12.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 364.8605 | 0.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.0552 | 2.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.0761 | 7.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.1094 | 3.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.1186 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.1230 | 11.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.1363 | 4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.1389 | 4.39 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.1424 | 16.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.2223 | 12.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.2342 | 15.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 365.3055 | 9.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 367.0674 | 9.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 367.1222 | 9.91 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 367.2451 | 16.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 367.2490 | 16.14 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 367.2663 | 17.32 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 368.0381 | 3.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 368.0567 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 368.7597 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 369.2019 | 16.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 369.2109 | 17.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 369.2120 | 16.73 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 369.2148 | 15.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 369.2470 | 16.38 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 370.1270 | 5.27 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 370.1340 | 17.01 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 370.2269 | 17.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 370.2522 | 16.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 370.3127 | 17.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 371.0194 | 10.73 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 371.0622 | 6.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 371.2234 | 17.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 371.2247 | 17.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 372.1061 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 372.1074 | 1.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 372.9063 | 2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 373.1910 | 11.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 373.1919 | 16.97 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 374.2255 | 5.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 375.0242 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 375.1003 | 7.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 375.1389 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 376.1369 | 8.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 376.2237 | 5.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 377.1074 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 377.1089 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 378.0152 | 1.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 378.0997 | 2.03 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 378.9195 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 378.9227 | 19.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 379.1024 | 7.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 379.1040 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 379.1571 | 17.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 379.2542 | 12.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 379.2734 | 17.48 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 380.1050 | 9.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.0415 | 1.28 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.1032 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.1198 | 14.58 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.1205 | 11.19 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.1211 | 14.34 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.1723 | 14.73 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.2319 | 14.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.2322 | 12.62 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.2325 | 13.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.2326 | 12.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 381.2369 | 15.67 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 382.1850 | 11.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 382.2392 | 14.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 382.2401 | 14.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 382.9898 | 0.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 382.9941 | 1.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 383.1486 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 383.1668 | 16.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 383.1883 | 13.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 383.1889 | 14.96 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 383.2718 | 16.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 383.3214 | 18.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.1298 | 1.63 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.1663 | 17.82 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.2543 | 5.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.7189 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.9338 | 0.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.9405 | 11.56 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 384.9921 | 1.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 385.0793 | 9.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 385.1945 | 17.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 385.2030 | 16.54 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 385.2059 | 15.5 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.0187 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.0961 | 1.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.1177 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.1274 | 15.31 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.1274 | 15.6 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.1500 | 5.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.2122 | 10.3 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.7164 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.8805 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 386.9417 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 387.1018 | 18.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 387.1639 | 14.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 387.2199 | 15.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 387.2910 | 12.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 388.0166 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 388.0175 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 389.0371 | 0.72 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 389.0490 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 389.0508 | 1.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 389.0625 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 390.0154 | 5.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 390.2025 | 16.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 390.8932 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 390.9074 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 390.9198 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 391.0545 | 9.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 391.1250 | 1.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 391.2883 | 15.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 391.9216 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 392.1026 | 7.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 392.8028 | 0.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 393.0225 | 1.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 393.1736 | 19.6 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.0416 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.0427 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.1128 | 3.16 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.2986 | 13.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.7475 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.8915 | 9.04 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.9744 | 1.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 394.9774 | 1.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 395.0546 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 395.0964 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 395.1106 | 15.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 395.1355 | 17.68 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 395.2253 | 17.03 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 395.2492 | 12.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.0338 | 0.95 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.0410 | 1.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.1461 | 4.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.2362 | 0.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.2480 | 17.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.7460 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.8518 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.8893 | 9.04 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.8952 | 19.5 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.9726 | 1.11 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 396.9751 | 1.45 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.0352 | 2.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.0944 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.0981 | 11.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.1864 | 1.9 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.2307 | 19.24 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.2424 | 17.53 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 397.3088 | 16.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 398.2395 | 17.54 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 398.2711 | 14.82 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 399.1310 | 16.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 399.1889 | 9.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.0051 | 1.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.0635 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.0877 | 16.52 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.2396 | 12.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.6951 | 0.84 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.9109 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 400.9155 | 17.8 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0116 | 1.37 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0315 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0828 | 7.39 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0835 | 7.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0883 | 15.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0917 | 15.69 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.0971 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.1238 | 15.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.1878 | 7.06 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.2226 | 6.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.2235 | 6.89 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 401.9879 | 0.86 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 402.1028 | 16.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 402.1224 | 4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 402.8029 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 402.9179 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 403.0517 | 2.08 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 403.0776 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 403.2522 | 14.66 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 403.2668 | 17.73 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 403.2688 | 17.2 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 403.2691 | 16.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 404.1209 | 4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 404.1564 | 2.05 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 404.8037 | 0.77 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 405.0300 | 1.35 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 405.0516 | 1.25 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 405.0931 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 405.1866 | 15.65 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 405.2227 | 16.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 405.8791 | 0.79 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 406.0453 | 1.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 406.1658 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 406.2055 | 16.23 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 406.9102 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 407.0485 | 4.15 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 407.0840 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 407.1914 | 14 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 407.1923 | 18.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 407.7783 | 0.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 408.0595 | 1.88 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 408.1274 | 8.01 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 408.1803 | 4.13 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 408.7450 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 408.9361 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.0195 | 1.44 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.0655 | 7.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.0951 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.1339 | 7.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.1515 | 19.62 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.1959 | 17.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.2401 | 18.02 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.2685 | 0.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.3155 | 19.33 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 409.9384 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.0564 | 1.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.0576 | 1.81 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.0848 | 3.17 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.1089 | 1.64 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.1263 | 8.61 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.2227 | 12.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.2436 | 19.24 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.7420 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 410.9325 | 0.74 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 411.0128 | 7.78 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 411.0613 | 4.85 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 411.0620 | 5.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 411.1308 | 4.57 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 411.1997 | 0.71 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 411.2111 | 17.98 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 412.1322 | 9.43 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 412.1499 | 4 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 412.7418 | 0.83 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 412.9696 | 12.93 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 412.9734 | 19.29 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 413.1042 | 3.07 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 413.1219 | 1.76 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells | |
| AN005416 | 413.1619 | 3.09 | Minutes | ST003305 | NEGATIVE | Waters Xevo-G2-XS | Reversed phase | Human | Cancer cells |
